APOE and Alzheimer disease: While there have been conflicting reports regarding the impact of APOE genotype on clinical progression among symptomatic AD patients66-70, the selection of these peptides and higher frequency of APOE ε4 in the AD-like AsymAD subgroup suggests that ε4 carriers are predisposed to more rapid decline and a shortened asymptomatic phase of AD.